Trial Condition(s):
Atrial Fibrillation
Observational study to assess sociodemographic and clinical features of patients treated with rivaroxaban in routine clinical practice of hematologists, cardiologists and internists of Spain (HEROIC)
Bayer Identifier:
17671
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
Depict demographic and clinical features of patients with atrial fibrillation treated with rivaroxaban to prevent stroke and pulmonary embolism in routine clinical practice
Inclusion Criteria
- Patients ≥ 18 years - Patients with atrial fibrillation - Patients in treatment with rivaroxaban for stroke prevention in atrial fibrillation at least 3 months previous to inclusion period in study
Exclusion Criteria
- Patients in treatment after start of study - Patients treated with other anticoagulant treatment
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Many Locations, Spain | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Observational and cross-sectional study to assess the sociodemographic and clinical characteristics of patients treated with RIVAROXABAN in the context of routine clinical practice of Spanish haematologists, cardiologists and internists (HEROIC study)
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Demographic DataTimeframe: At recruitment visit
- Medical HistoryTimeframe: At recruitment visit
Secondary Outcome
- Assess regional differences among the different Spanish autonomous communities on the management of patients with rivaroxaban treatment during the routine clinical practiceBy use of Informe de Posicionamiento Terapéutico (Spanish Questionnaire)Timeframe: At recruitment visit
- Adherence to rivaroxaban treatmentBy use of Morisky-Green questionnaireTimeframe: At recruitment visit
- Assess the satisfaction of rivaroxaban treatmentBy use of Anti-Clot Treatment Scale (ACTS) questionnaireTimeframe: At recruitment visit
- Assess the quality of life in patientsBy use of Short-Form 12 Health Survey,version 2 (SF12v2) questionnaireTimeframe: At recruitment visit
Additional Information
Copyright © Bayer
Powered by
